COVID-19 Results Briefing

The South-East Asia Region

March 6, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in the South-East Asia Region. The model was run on March 6, 2021, with data through March 1, 2021.

Daily infections and deaths increased in the South-East Asia Region over the past week despite declining seasonality and vaccination campaigns. This is likely due to high levels of mobility, reduced vigilance in adhering to social distancing guidelines, and the recent detection of the B.1.1.7 variant in western India. Our model this week includes reduced cross-variant immunity between ancestral variants and B.1.1.7 with the escape variants (B.1.351 and P1). This reduced protection from natural infection will have a substantial impact on the epidemic later in the year as the escape variants increase in prevalence, but likely does not have a major effect in the next four months. The trajectory of the pandemic depends heavily on future behaviors and increased vaccination. We currently project about 414,000 cumulative deaths on July 1, 2021. This represents 45,000 additional deaths from March 1 to July 1. Daily deaths will likely remain at current levels over the next several months, with moderate declines at the start of summer when seasonality is lowest. If universal mask coverage (95%) were attained in the next week, our model projects about 11,000 fewer cumulative deaths compared to the reference scenario on July 1, 2021.

Strategies to reduce the death toll include increasing vaccinations, reinforcing the importance of continued mask wearing, and encouraging the public to continue avoiding high transmission risk settings – like large public gatherings – through mandates and public messaging.

Current situation

- Daily reported cases in the last week increased to 24,300 per day on average compared to 22,300 the week before (Figure 1).
- Daily deaths in the last week increased to 480 per day on average compared to 420 the week before (Figure 2). This makes COVID-19 the number 18 cause of death in the South-East Asia Region this week (Table 1).
- Effective R, computed using cases, hospitalizations, and deaths, is not greater than 1 in any location (Figure 23).
- We estimated that 13% of people in the South-East Asia Region have been infected as of March 1 (Figure 4).
- No locations in the region had daily death rates greater than 4 per million (Figure 3).
Trends in drivers of transmission

- Mobility last week was 14% lower than the pre-COVID-19 baseline (Figure 8). Mobility was near baseline (within 10%) in Bangladesh, Nepal, and the majority of India’s states. Mobility was lower than 30% of baseline in Myanmar and Sri Lanka.

- As of March 1, we estimated that 64% of people always wore a mask when leaving their home (Figure 10). Mask use was lower than 50% in Maldives.

- There were 44 diagnostic tests per 100,000 people on March 1 (Figure 12).

- In the South-East Asia Region, 73.7% of people say they would accept or would probably accept a vaccine for COVID-19. The fraction of the population who are open to receiving a COVID-19 vaccine ranges from 71% in North Korea to 79% in Myanmar (Figure 15).

- In our current reference scenario, we expect that over 1 billion people will be vaccinated in the South-East Asia Region by July 1 (Figure 16).

Projections

- In our reference scenario, which represents what we think is most likely to happen, our model projects 414,000 cumulative deaths on July 1, 2021. This represents 45,000 additional deaths from March 1 to July 1 (Figure 17). Daily deaths will remain at current levels for several weeks, peaking again at 550 on March 21, 2021, with continued slow declines through the start of summer (Figure 18).

- By July 1, 2021, we project that 5,500 lives will be saved by the projected vaccine rollout.

- If universal mask coverage (95%) were attained in the next week, our model projects 11,000 fewer cumulative deaths compared to the reference scenario on July 1, 2021 (Figure 17).

- Under our worse scenario, our model projects 418,000 cumulative deaths on July 1, 2021 (Figure 17).

- Figure 20 compares our reference scenario forecasts to other publicly archived models. Forecasts are widely divergent.

- At some point from March through July 1, one country – Indonesia – will have high or extreme stress on hospital beds (Figure 21). At some point from March through July 1, no countries will have high or extreme stress on ICU capacity (Figure 22).
Model updates

This week we have modified our SEIR model to allow for reduced cross-variant immunity. The placebo arm of the Novavax South African trial suggests that infection with ancestral variants provided no protection against B.1.351. Over the last three months, the epidemic in Amazonas, Brazil – where more than 70% of the population were previously infected – also suggests that the P.1 variant is likely infecting at high rates those individuals who were previously infected with ancestral variants. Based on these observations, we have modified the SEIR framework to allow for no or partial protection from infection with ancestral variants or B.1.1.7 against B.1.351 or P.1. In this more elaborated model, two critical assumptions substantially determine the impact of new variant scale-up: 1) protection against B.1.351 or P.1 from ancestral or B.1.1.7 infection, and 2) the increase in transmissibility of B.1.351 or P.1 compared to the increment seen in B.1.1.7. The elaborated SEIR model has the compartments shown below. The actual number of compartments is larger, since we track high-risk and low-risk individuals separately.

In our reference scenario, or what we think is most likely to occur, we sample from a uniform distribution ranging from 25% to 50% cross-variant immunity. In the worse scenario, we sample from a uniform distribution ranging from 0% to 50% cross-variant immunity. In the reference scenario, we also assume that the probability of transmission for B.1.351 and P.1 is 25%–75% that of the increase of B.1.1.7 over ancestral variants. This range has been selected to approximate the observed scale-up of the B.1.351 variant in South Africa under conditions of reduced cross-variant immunity. In the worse scenario, the probability of transmission for B.1.351 and P.1 is assumed to be 0–50% of the increase of B.1.1.7 over ancestral variants. The introduction of reduced cross-variant immunity has important impacts in the next four months in settings (such as Brazil) with high ancestral variant cumulative infection and the presence of B.1.351 or P.1. In other settings, with lower cumulative infection from ancestral variants and low prevalence of these escape variants, the impact in our forecasts over the next four months is less pronounced.
Figure 1. Reported daily COVID-19 cases

Table 1. Ranking of COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

<table>
<thead>
<tr>
<th>Cause name</th>
<th>Weekly deaths</th>
<th>Ranking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>39,868</td>
<td>1</td>
</tr>
<tr>
<td>Stroke</td>
<td>27,102</td>
<td>2</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>21,984</td>
<td>3</td>
</tr>
<tr>
<td>Diarrheal diseases</td>
<td>14,328</td>
<td>4</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
<td>11,327</td>
<td>5</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>10,815</td>
<td>6</td>
</tr>
<tr>
<td>Neonatal disorders</td>
<td>10,504</td>
<td>7</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>9,152</td>
<td>8</td>
</tr>
<tr>
<td>Cirrhosis and other chronic liver diseases</td>
<td>8,514</td>
<td>9</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>6,390</td>
<td>10</td>
</tr>
<tr>
<td>COVID-19</td>
<td>3,361</td>
<td>18</td>
</tr>
</tbody>
</table>
Figure 2. Reported daily COVID-19 deaths
Figure 3. Daily COVID-19 death rate per 1 million on March 01, 2021

Figure 4. Estimated percent of the population infected with COVID-19 on March 01, 2021
Figure 5. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model.

*Due to measurement errors in cases and testing rates, the infection to detection rate (IDR) can exceed 100% at particular points in time.*
Figure 6. Percent of circulating SARS-CoV-2 for 3 primary variants on March 1, 2021.

A. Percent B.1.1.7 variant

B. Percent B.1.351 variant

C. Percent P1 variant
**Figure 7.** Infection fatality ratio on March 01, 2021. This is estimated as the ratio of COVID-19 deaths to infections based on the SEIR disease transmission model.
## Critical drivers

**Table 2.** Current mandate implementation

<table>
<thead>
<tr>
<th>Country</th>
<th>All nonessential businesses closed</th>
<th>Any businesses restricted</th>
<th>Any gatherings restricted</th>
<th>Mask use</th>
<th>School closure</th>
<th>Stay home order</th>
<th>Travel limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangladesh</td>
<td>Mandate in place</td>
<td>Mandate in place</td>
<td>Mandate in place</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bhutan</td>
<td>No mandate (imposed this week)</td>
<td>No mandate (imposed this week)</td>
<td>No mandate (imposed this week)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Democratic People’s Republic of Korea</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>India</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maldives</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myanmar</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nepal</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timor-Leste</td>
<td>No mandate</td>
<td>No mandate</td>
<td>No mandate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Not all locations are measured at the subnational level.*
Figure 8. Trend in mobility as measured through smartphone app use compared to January 2020 baseline

Figure 9. Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on March 01, 2021
Figure 10. Trend in the proportion of the population reporting always wearing a mask when leaving home.

Figure 11. Proportion of the population reporting always wearing a mask when leaving home on March 01, 2021.
**Figure 12.** Trend in COVID-19 diagnostic tests per 100,000 people

![Graph showing trend in COVID-19 diagnostic tests per 100,000 people]

**Figure 13.** COVID-19 diagnostic tests per 100,000 people on February 26, 2021

![Map showing regional distribution of COVID-19 diagnostic tests on February 26, 2021]
Figure 14. Increase in the risk of death due to pneumonia on February 1 2020 compared to August 1 2020.
Figure 15. This figure shows the estimated proportion of the adult (18+) population that is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).

Figure 16. The number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.
Projections and scenarios

We produce three scenarios when projecting COVID-19. The **reference scenario** is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the UK.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.

The **worse scenario** modifies the reference scenario assumptions in three ways:

- First, it assumes that variants B.1.351 or P1 begin to spread within 3 weeks in adjacent locations that do not already have B.1.351 or P1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The **universal masks scenario** makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.
Figure 17. Cumulative COVID-19 deaths until July 01, 2021 for three scenarios

Figure 18. Daily COVID-19 deaths until July 01, 2021 for three scenarios
Figure 19. Daily COVID-19 infections until July 01, 2021 for three scenarios
Figure 20. Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology (Delphi; https://www.covidanalytics.io/home), Imperial College London (Imperial; https://www.covidsim.org), The Los Alamos National Laboratory (LANL; https://covid-19.bsvgateway.org/), and the SI-KJalpha model from the University of Southern California (SIKJalpha; https://github.com/scc-usc/ReCOVER-COVID-19). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.
Figure 21. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered low stress, 5-9% is considered moderate stress, 10-19% is considered high stress, and greater than 20% is considered extreme stress.
Figure 22. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered low stress, 10-29% is considered moderate stress, 30-59% is considered high stress, and greater than 60% is considered extreme stress.
More information

Data sources:

Mask use data sources include PREMISE; Facebook Global symptom survey (This research is based on survey results from University of Maryland Social Data Science Center) and the Facebook United States symptom survey (in collaboration with Carnegie Mellon University); Kaiser Family Foundation; YouGov COVID-19 Behaviour Tracker survey.

Vaccine hesitancy data are from the COVID-19 Beliefs, Behaviors, and Norms Study, a survey conducted on Facebook by the Massachusetts Institute of Technology (https://covidsurvey.mit.edu/).

Data on vaccine candidates, stages of development, manufacturing capacity, and pre-purchasing agreements are primarily from Linksbridge and supplemented by Duke University.

A note of thanks:

We wish to warmly acknowledge the support of these and others who have made our COVID-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit http://www.healthdata.org/covid.